Both biotechs have been struggling for a while, but there might be some hope for them.The COVID-19 vaccine was worth tens of billions of dollars, but most of it went into the hands of Moderna and Pfizer. Smaller biotechs that tried to dominate this market were much less successful. That group includes Novavax (NVAX 6.71%) and Inovio Pharmaceuticals (INO 0.94%). The former did launch a coronavirus vaccine in the U.S., but the latter never got that far.Both have substantially lagged the market over the past t ...